Wanbury reports strong Q2, H1 FY26 financial performance

Wanbury Limited demonstrated robust financial results for Q2 and H1 FY26, with Q2 FY26 EBITDA reaching ₹26.0 crore (16.2%), marking a 20% growth quarter-over-quarter. Profit after tax (PAT) for Q2 FY26 was ₹15.2 crore, an approximate 90% increase from ₹8.0 crore in Q2 FY25, driven by cost efficiencies, improved product yield, and lower finance costs. The company's total revenue from operations for Q2 FY26 was ₹160.06 crore, contributing to a H1 FY26 revenue of ₹323.2 crore, a 10.57% year-over-year increase.

The API business saw a Q2 FY26 revenue of ₹135 crore, while formulations business revenue for the same period was ₹22 crore. The company achieved a record operational EBITDA of ₹80 crore in FY25. Debt has been reduced by 75% from its peak, and borrowing costs have decreased from 22.5% to 12.5%, effective March 1, 2025.

Operational highlights include a 25% increase in Metformin and a 20% increase in Sertraline capacity over the last three years, achieved through de-bottlenecking projects. Wanbury also successfully launched its new brand, C-Red (an advanced liposomal iron supplement), contributing to the formulations business becoming EBITDA positive.